Pfizer PFE Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Pfizer in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pfizer's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Pfizer's financing cash flow?
- Pfizer (PFE) reported financing cash flow of -$2.86B in Q1 2026.
- How has Pfizer's financing cash flow changed year-over-year?
- Pfizer's financing cash flow increased by 45.4% year-over-year, from -$5.23B to -$2.86B.
- What is the long-term trend for Pfizer's financing cash flow?
- Over 2 years (2021 to 2025), Pfizer's financing cash flow has grown at a 5.4% compound annual growth rate (CAGR), from -$9.82B to -$10.9B.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.